Developer docs
API playgroundTry for free, no card

Search company profiles

Sensydia

Full company profile

uuid00029pa

Namestring
Sensydia
Legal namestring
Sensydia Corporation
Websiteurl
sensydia.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Sensydia Corporation is a privately held medical technology company founded in 2015 and headquartered in Valencia, California (Los Angeles area), operating with 1–10 employees. The company develops the Cardiac Performance System (CPS), a portable, point-of-care platform that combines proprietary broad-band acoustic sensors and ECG biosensors with proprietary waveform machine learning algorithms to deliver non-invasive hemodynamic measurements — Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP) — that the company positions as accuracy-equivalent to gold-standard invasive right heart catheterization. The system captures heart sounds and electrical signals, processes them via ML models trained against catheterization lab data, and transmits results via WiFi or Bluetooth to a tablet or cloud in real time, enabling measurement in under five minutes by non-specialist operators across ICU, ER, cardiology office, clinic, and home settings.

The CPS device received FDA 510(k) clearance for Ejection Fraction measurement in 2018 and FDA Breakthrough Device Designation in 2022; the company is currently conducting a multi-center pivotal clinical study (first site enrolled April 2025 at Huntsville Hospital Heart Center) to support FDA submission for expanded CO and PAP indications. Sensydia is also the industry-first beneficiary of AMA Category III CPT code 1036T (published December 2025, effective July 2026), which establishes a dedicated reimbursement pathway for noninvasive augmentative AI hemodynamic assessment. The company is led by CEO Anthony Arnold (ex-Boston Scientific, ex-Medtronic), President & COO Rusty Page (ex-Neuronetics, founding team at Bioness), CTO William Kaiser (UCLA Distinguished Professor of Electrical and Computer Engineering), and CMO Dr. Aman Mahajan (UPMC Department Chair of Anesthesiology), with former Medtronic Chairman & CEO William Hawkins serving as an advisor.

The business model is anchored on hardware sales of the CPS device to hospitals, cardiology practices, and outpatient clinics, with the new CPT code establishing a recurring reimbursement pathway for clinical services performed using the device. To date, Sensydia has raised approximately $8M in equity (May 2023 round led by Orlando Health Ventures with Colle Capital and Frontier Venture Capital) supplemented by a $3M NIH Fast-Track STTR grant and earlier rounds totaling roughly $9.8M since 2016. Customer relationships currently visible in the data are clinical research partnerships (UCLA, U of Minnesota, OHSU, UPMC, Huntsville Hospital) rather than commercial accounts, reflecting the company's pre-commercial / investigational status.

Short descriptiontext

Sensydia Corporation is a Los Angeles–area medical technology company that develops the Cardiac Performance System (CPS), a portable, AI-driven platform combining proprietary acoustic sensors and machine learning to deliver non-invasive hemodynamic measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure) for hospitals, cardiology offices, and critical care settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersValencia, United States
HQ citystring
Valencia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive hemodynamic monitoring, cardiac assessment devices, biosensor cardiac diagnostics, heart failure diagnostics, pulmonary hypertension screening
Industry3 codes
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Monitoring Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CPS Device Sales
TypeHardware Sales
Description

Sale of the Cardiac Performance System hardware device to hospitals, clinics, and medical offices. The company plans to commercialize CPS following FDA approval for additional indications beyond the 2018 EF clearance.

dlvr.it
2Reimbursement via CPT Code
TypeTransaction Fee
Description

With the new AMA Category III CPT code 1036T (effective July 1, 2026), Sensydia will receive reimbursement for non-invasive AI hemodynamic assessment services. This establishes a pathway for sustainable revenue from healthcare providers using CPS.

sensydia.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Cardiac Performance System (CPS)
Description

Non-invasive hemodynamic measurement platform that uses biosensors and AI to assess heart function including Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP).

sensydia.com
Core offering1 text field

Sensydia develops and sells the Cardiac Performance System (CPS), a portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with proprietary machine learning algorithms to deliver rapid measurement of Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP). The handheld device provides gold-standard-equivalent accuracy in under five minutes at the point of care and transmits results via WiFi or Bluetooth to tablets or the cloud, targeting hospitals, cardiologists, and outpatient medical offices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • CPS identified patients with elevated mPAP (>35mmHg) with AUC of 0.80 and (>30mmHg) with AUC of 0.77 in clinical study
+4 more records
Product overview1 text field

Sensydia offers a single unified product platform: the Cardiac Performance System (CPS), a non-invasive hemodynamic assessment platform that combines proprietary biosensors (broad-band acoustic and ECG sensors) with AI/machine learning algorithms. The CPS platform delivers multiple cardiac measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure, Pulmonary Artery Occlusion Pressure) through one automated handheld device, positioned as a replacement for invasive catheterization procedures. The platform uses cloud-based data transmission and is designed for use in hospitals, clinics, and telemedicine settings. The company received FDA 510(k) clearance for Ejection Fraction measurement in 2018 and is pursuing additional FDA clearances for other hemodynamic parameters through an ongoing pivotal clinical study.

Product and service1 record
1Cardiac Performance System (CPS)
CategoryCardiac Monitoring Devices
Description

Portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with machine learning algorithms to deliver automated measurement of Ejection Fraction (EF), Cardiac Output (CO), Pulmonary Artery Pressure (PAP), and Pulmonary Artery Occlusion Pressure (PAOP) in under five minutes. Results are transmitted via WiFi or Bluetooth to tablets or the cloud for point-of-care use in hospitals, cardiology offices, clinics, and telemedicine settings. FDA 510(k) cleared for EF in 2018; additional hemodynamic parameters under clinical validation for expanded FDA indications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research partner conducting 50-subject development study for pulmonary pressure algorithms. Dr. Tamas Alexy served as Principal Investigator. University of Minnesota investigators presented ACC 2025 clinical findings.

2Ronald Reagan UCLA Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site that contributed to FDA clearance for Sensydia's ejection fraction algorithm.

sensydia.com
3OHSU Knight Cardiovascular Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site for cardiac output algorithm development.

sensydia.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study site for pulmonary pressure algorithm and general clinical utility studies. Dr. Aman Mahajan serves as Chief Medical Officer of Sensydia and is affiliated with UPMC. Collaborating on NIH grant clinical utility studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

First site enrolled in Sensydia's multi-center pivotal study evaluating CPS accuracy compared to gold-standard invasive right heart catheterization. Dr. James D. Murphy, MD, FACC serving as Principal Investigator.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Maker of AI-enabled digital stethoscopes (CORE 500, DUO) with FDA-cleared algorithms for detecting atrial fibrillation, heart murmurs, and low ejection fraction. Adjacent AI-cardiac monitoring competitor focused on the ambulatory and clinic setting.

TypeBroad incumbent
Description

Provides integrated ICU and perioperative patient monitoring platforms including the CARESCAPE and Portrait systems, covering ECG, SpO2, and invasive hemodynamic parameters. Incumbent hospital channel competitor with established procurement and EMR integration.

TypeEmerging player
Description

Provides the Zio long-term ambulatory ECG cardiac monitoring patch with AI-based arrhythmia detection. Comparable as a clinically validated, AI-driven ambulatory cardiac monitoring device, although focused on rhythm rather than hemodynamic assessment.

TypeDirect peer
Description

USCOM manufactures the USCOM 1A non-invasive Doppler-based cardiac output monitor, used in emergency, ICU, and pediatric care. Competes head-to-head with Sensydia on point-of-care, non-invasive hemodynamic assessment.

TypeDirect peer
Description

A leading patient-monitoring company with non-invasive rainbow SET technology covering SpO2, hemoglobin, and respiration, increasingly expanding into multi-parameter continuous vital-sign monitoring. Competitor for clinical-grade vital signs capture in the same hospital channels Sensydia targets.

TypeBroad incumbent
Description

Global leader in hemodynamic monitoring, with the Swan-Ganz pulmonary artery catheter as the gold standard for invasive CO/PAP measurement and the ClearSight/Finapres non-invasive finger-cuff system. Directly competes with Sensydia's target use cases across the hospital hemodynamic monitoring workflow.

TypeBroad incumbent
Description

Offers the IntelliVue and X3/X4 patient monitoring platforms with extensive hemodynamic and ECG modules across ICU, ER, and step-down. Broad incumbent competing for hospital monitoring spend and EHR-integrated bedside data.

TypeEmerging player
Description

Develops the Vitalstream continuous non-invasive blood pressure and hemodynamic monitor using a finger-cuff pulse-wave analysis method. Closely adjacent competitor in wireless, non-invasive hemodynamic monitoring for hospital and ambulatory use.

9Abbott (CardioMEMS)
TypeBroad incumbent
Description

Abbott's CardioMEMS HF System is an implantable pulmonary artery pressure sensor for remote heart-failure monitoring — a direct alternative in the pulmonary hypertension / heart failure management use case Sensydia addresses, though invasive rather than non-invasive.

TypeDirect peer
Description

Baxter acquired Cheetah Medical, whose Starling SV / NICOM platform provides non-invasive continuous cardiac output and stroke volume monitoring using bioreactance. Most direct non-invasive hemodynamic competitor to Sensydia's CPS in the ICU and ER.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sensydia

Cardiac Monitoring Devicessensydia.com

Sensydia Corporation is a Los Angeles–area medical technology company that develops the Cardiac Performance System (CPS), a portable, AI-driven platform combining proprietary acoustic sensors and machine learning to deliver non-invasive hemodynamic measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure) for hospitals, cardiology offices, and critical care settings.

What Sensydia does

Sensydia Corporation is a privately held medical technology company founded in 2015 and headquartered in Valencia, California (Los Angeles area), operating with 1–10 employees. The company develops the Cardiac Performance System (CPS), a portable, point-of-care platform that combines proprietary broad-band acoustic sensors and ECG biosensors with proprietary waveform machine learning algorithms to deliver non-invasive hemodynamic measurements — Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP) — that the company positions as accuracy-equivalent to gold-standard invasive right heart catheterization. The system captures heart sounds and electrical signals, processes them via ML models trained against catheterization lab data, and transmits results via WiFi or Bluetooth to a tablet or cloud in real time, enabling measurement in under five minutes by non-specialist operators across ICU, ER, cardiology office, clinic, and home settings.

The CPS device received FDA 510(k) clearance for Ejection Fraction measurement in 2018 and FDA Breakthrough Device Designation in 2022; the company is currently conducting a multi-center pivotal clinical study (first site enrolled April 2025 at Huntsville Hospital Heart Center) to support FDA submission for expanded CO and PAP indications. Sensydia is also the industry-first beneficiary of AMA Category III CPT code 1036T (published December 2025, effective July 2026), which establishes a dedicated reimbursement pathway for noninvasive augmentative AI hemodynamic assessment. The company is led by CEO Anthony Arnold (ex-Boston Scientific, ex-Medtronic), President & COO Rusty Page (ex-Neuronetics, founding team at Bioness), CTO William Kaiser (UCLA Distinguished Professor of Electrical and Computer Engineering), and CMO Dr. Aman Mahajan (UPMC Department Chair of Anesthesiology), with former Medtronic Chairman & CEO William Hawkins serving as an advisor.

The business model is anchored on hardware sales of the CPS device to hospitals, cardiology practices, and outpatient clinics, with the new CPT code establishing a recurring reimbursement pathway for clinical services performed using the device. To date, Sensydia has raised approximately $8M in equity (May 2023 round led by Orlando Health Ventures with Colle Capital and Frontier Venture Capital) supplemented by a $3M NIH Fast-Track STTR grant and earlier rounds totaling roughly $9.8M since 2016. Customer relationships currently visible in the data are clinical research partnerships (UCLA, U of Minnesota, OHSU, UPMC, Huntsville Hospital) rather than commercial accounts, reflecting the company's pre-commercial / investigational status.

Sensydia firmographics

Firmographics
Name
Sensydia
Legal name
Sensydia Corporation
Website
https://sensydia.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Sensydia Corporation is a Los Angeles–area medical technology company that develops the Cardiac Performance System (CPS), a portable, AI-driven platform combining proprietary acoustic sensors and machine learning to deliver non-invasive hemodynamic measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure) for hospitals, cardiology offices, and critical care settings.
Ownership category
akta.pro rank

Sensydia industry classification

Industry
Product category
Cardiac Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Non-invasive hemodynamic monitoring
  • Cardiac assessment devices
  • Biosensor cardiac diagnostics
  • Heart failure diagnostics
  • Pulmonary hypertension screening

Where Sensydia is headquartered

Location

Headquarters

HQ city
Valencia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sensydia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. CPS Device Sales: Sale of the Cardiac Performance System hardware device to hospitals, clinics, and medical offices. The company plans to commercialize CPS following FDA approval for additional indications beyond the 2018 EF clearance.
  2. Reimbursement via CPT Code: With the new AMA Category III CPT code 1036T (effective July 1, 2026), Sensydia will receive reimbursement for non-invasive AI hemodynamic assessment services. This establishes a pathway for sustainable revenue from healthcare providers using CPS.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Sensydia product offering

Product offering

Core offering

Sensydia develops and sells the Cardiac Performance System (CPS), a portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with proprietary machine learning algorithms to deliver rapid measurement of Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP). The handheld device provides gold-standard-equivalent accuracy in under five minutes at the point of care and transmits results via WiFi or Bluetooth to tablets or the cloud, targeting hospitals, cardiologists, and outpatient medical offices.

Product overview

Sensydia offers a single unified product platform: the Cardiac Performance System (CPS), a non-invasive hemodynamic assessment platform that combines proprietary biosensors (broad-band acoustic and ECG sensors) with AI/machine learning algorithms. The CPS platform delivers multiple cardiac measurements (Ejection Fraction, Cardiac Output, Pulmonary Artery Pressure, Pulmonary Artery Occlusion Pressure) through one automated handheld device, positioned as a replacement for invasive catheterization procedures. The platform uses cloud-based data transmission and is designed for use in hospitals, clinics, and telemedicine settings. The company received FDA 510(k) clearance for Ejection Fraction measurement in 2018 and is pursuing additional FDA clearances for other hemodynamic parameters through an ongoing pivotal clinical study.

Differentiator

Problem solved

Functional benefit

Brands

  • Cardiac Performance System (CPS): Non-invasive hemodynamic measurement platform that uses biosensors and AI to assess heart function including Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP).

Products and services

  • Cardiac Performance System (CPS) Portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with machine learning algorithms to deliver automated measurement of Ejection Fraction (EF), Cardiac Output (CO), Pulmonary Artery Pressure (PAP), and Pulmonary Artery Occlusion Pressure (PAOP) in under five minutes. Results are transmitted via WiFi or Bluetooth to tablets or the cloud for point-of-care use in hospitals, cardiology offices, clinics, and telemedicine settings. FDA 510(k) cleared for EF in 2018; additional hemodynamic parameters under clinical validation for expanded FDA indications.

Quantifiable outcome

  • CPS identified patients with elevated mPAP (>35mmHg) with AUC of 0.80 and (>30mmHg) with AUC of 0.77 in clinical study
  • +4 more outcomes

Companies that use Sensydia

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Sensydia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Sensydia partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • University of Minnesota Medical SchoolcoreStrategic or Co-development PartnerClinical research partner conducting 50-subject development study for pulmonary pressure algorithms. Dr. Tamas Alexy served as Principal Investigator. University of Minnesota investigators presented ACC 2025 clinical findings.
  • Ronald Reagan UCLA Medical CentercoreStrategic or Co-development PartnerClinical study site that contributed to FDA clearance for Sensydia's ejection fraction algorithm.
  • OHSU Knight Cardiovascular InstitutecoreStrategic or Co-development PartnerClinical study site for cardiac output algorithm development.
  • University of Pittsburgh Medical Center (UPMC)coreStrategic or Co-development PartnerClinical study site for pulmonary pressure algorithm and general clinical utility studies. Dr. Aman Mahajan serves as Chief Medical Officer of Sensydia and is affiliated with UPMC. Collaborating on NIH grant clinical utility studies.
  • Huntsville Hospital Heart CentercoreStrategic or Co-development PartnerFirst site enrolled in Sensydia's multi-center pivotal study evaluating CPS accuracy compared to gold-standard invasive right heart catheterization. Dr. James D. Murphy, MD, FACC serving as Principal Investigator.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Sensydia competitors and assessment

Company assessment

Emerging players

  • Eko Health: Maker of AI-enabled digital stethoscopes (CORE 500, DUO) with FDA-cleared algorithms for detecting atrial fibrillation, heart murmurs, and low ejection fraction. Adjacent AI-cardiac monitoring competitor focused on the ambulatory and clinic setting.
  • iRhythm Technologies: Provides the Zio long-term ambulatory ECG cardiac monitoring patch with AI-based arrhythmia detection. Comparable as a clinically validated, AI-driven ambulatory cardiac monitoring device, although focused on rhythm rather than hemodynamic assessment.
  • Caretaker Medical: Develops the Vitalstream continuous non-invasive blood pressure and hemodynamic monitor using a finger-cuff pulse-wave analysis method. Closely adjacent competitor in wireless, non-invasive hemodynamic monitoring for hospital and ambulatory use.

Broad incumbents

  • GE HealthCare: Provides integrated ICU and perioperative patient monitoring platforms including the CARESCAPE and Portrait systems, covering ECG, SpO2, and invasive hemodynamic parameters. Incumbent hospital channel competitor with established procurement and EMR integration.
  • Edwards Lifesciences: Global leader in hemodynamic monitoring, with the Swan-Ganz pulmonary artery catheter as the gold standard for invasive CO/PAP measurement and the ClearSight/Finapres non-invasive finger-cuff system. Directly competes with Sensydia's target use cases across the hospital hemodynamic monitoring workflow.
  • Philips: Offers the IntelliVue and X3/X4 patient monitoring platforms with extensive hemodynamic and ECG modules across ICU, ER, and step-down. Broad incumbent competing for hospital monitoring spend and EHR-integrated bedside data.
  • Abbott (CardioMEMS): Abbott's CardioMEMS HF System is an implantable pulmonary artery pressure sensor for remote heart-failure monitoring — a direct alternative in the pulmonary hypertension / heart failure management use case Sensydia addresses, though invasive rather than non-invasive.

Direct peers

  • USCOM: USCOM manufactures the USCOM 1A non-invasive Doppler-based cardiac output monitor, used in emergency, ICU, and pediatric care. Competes head-to-head with Sensydia on point-of-care, non-invasive hemodynamic assessment.
  • Masimo: A leading patient-monitoring company with non-invasive rainbow SET technology covering SpO2, hemoglobin, and respiration, increasingly expanding into multi-parameter continuous vital-sign monitoring. Competitor for clinical-grade vital signs capture in the same hospital channels Sensydia targets.
  • Baxter International (Cheetah Medical): Baxter acquired Cheetah Medical, whose Starling SV / NICOM platform provides non-invasive continuous cardiac output and stroke volume monitoring using bioreactance. Most direct non-invasive hemodynamic competitor to Sensydia's CPS in the ICU and ER.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Sensydia social profiles

Digital presence

Sensydia compliance and trust

Trust signal

Compliance2 records

Sensydia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sensydia leadership team

Management profile

Number of profiles

Profiles5 records

Sensydia funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sensydia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sensydia

What does Sensydia do?

Sensydia develops and sells the Cardiac Performance System (CPS), a portable, non-invasive hemodynamic measurement platform that uses proprietary broad-band acoustic and ECG biosensors combined with proprietary machine learning algorithms to deliver rapid measurement of Ejection Fraction (EF), Cardiac Output (CO), and Pulmonary Artery Pressure (PAP). The handheld device provides gold-standard-equivalent accuracy in under five minutes at the point of care and transmits results via WiFi or Bluetooth to tablets or the cloud, targeting hospitals, cardiologists, and outpatient medical offices.

Is Sensydia a public or private company?

Sensydia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sensydia founded?

Sensydia was founded in 2015. It employs 11 to 50 people.

Where is Sensydia based?

Sensydia is headquartered in Valencia, United States, in the North America region.

How does Sensydia make money?

Two revenue lines are on record. CPS Device Sales are the primary driver. The others are reimbursement via CPT Code.

Who are Sensydia's main competitors?

Emerging players on record are Eko Health, iRhythm Technologies and Caretaker Medical. Broad incumbents are GE HealthCare, Edwards Lifesciences, Philips and Abbott (CardioMEMS). Direct peers are USCOM, Masimo and Baxter International (Cheetah Medical).

Does Sensydia have an API?

No public API is recorded for Sensydia.

What industry is Sensydia in?

Sensydia's product category is Cardiac Monitoring Devices. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizSensydia Appoints Brit Gould Chief Commercial Officer to Lead Cardiac Performance System LaunchSensydia promoted Brit Gould to Chief Commercial Officer to lead commercialization of its Cardiac Performance System. Gould will oversee strategy, reimbursement, and launch, building on his prior role as VP of Marketing. The company is advancing CPS through the ACOUSTIC-1 study and has received FDA Breakthrough Device designation.PR NewswireSensydia Appoints Brit Gould as Chief Commercial Officer to Lead Commercialization of the Cardiac Performance System (CPS™)Sensydia appointed Brit Gould as Chief Commercial Officer to lead commercialization of its Cardiac Performance System. Gould, who has led commercialization since 2024, will oversee strategy, reimbursement, and launch preparation, including establishing the first customer accounts. The company's CPS has received FDA Breakthrough Device designation.Pulse 2.0Sensydia Raises More Than $6 Million To Advance Cardiac Performance System Toward FDA AuthorizationSensydia raised over $6 million in financing led by Colle Capital Partners to advance its Cardiac Performance System. The funding will support clinical development toward FDA authorization and commercialization preparations. The system is investigational and has not yet received FDA authorization.Medical BuyerSensydia closes USD 6M funding roundSensydia closed an oversubscribed initial closing of over $6 million, led by Colle Capital Partners with Orlando Health Ventures. Proceeds will fund the Cardiac Performance System's ACOUSTIC-1 study to FDA authorization and commercial launch. A new CPT code for non-invasive hemodynamic assessment took effect in July 2026.citybizSensydia Raises Over $6 Million to Advance Cardiac Performance System Toward FDA AuthorizationSensydia raised over $6 million in an oversubscribed financing round led by Colle Capital Partners with Orlando Health Ventures. The funds will support its Cardiac Performance System through the ACOUSTIC-1 study and FDA authorization. The company plans to prepare for commercial launch.VC News DailySensydia Completes $6M+ Funding RoundSensydia, a clinical-stage medical technology company, announced an oversubscribed initial closing of $6+ million in its latest financing. The round was led by Colle Capital Partners with support from Orlando Health Ventures. Proceeds will carry its Cardiac Performance System through the ACOUSTIC'1 study to FDA authorization and support commercial launch preparation.Startup ResearcherSensydia Raises Over $6 Million for Cardiac Performance SystemSensydia raised over $6 million in an oversubscribed financing round led by Colle Capital Partners with Orlando Health Ventures. The funds will support its Cardiac Performance System through the ACOUSTIC-1 study to FDA authorization. The company expects the new CPT code to integrate non-invasive hemodynamic assessment into routine care.PR NewswireSensydia Secures Oversubscribed Funding to Deliver Groundbreaking Cardiac Performance System to the Office, Hospital, and ClinicSensydia closed an oversubscribed $6 million financing round led by Colle Capital Partners with Orlando Health Ventures support. Proceeds will fund the ACOUSTIC-1 study for its Cardiac Performance System and prepare for commercial launch. The system aims to provide non-invasive pulmonary pressure assessments in office settings.BioWorldSensydia lands $8M for AI-powered cardiac assessment toolSensydia Corp. secured $8 million in a financing round to advance its Cardiac Performance System, an AI-powered platform for detecting heart failure and pulmonary hypertension. The funds will be utilized to finalize product development, acquire manufacturing tooling, and submit the device to the U.S. FDA.PR NewswireSensydia Announces American Medical Association Category III CPT® Code for Noninvasive AI Hemodynamic AssessmentSensydia announced that the American Medical Association has published a new Category III CPT code (1036T) for noninvasive AI hemodynamic assessment, encompassing Sensydia's Cardiac Performance System (CPS), with the code effective July 1, 2026. The code establishes a reimbursement pathway for CPS, which uses non-invasive sensors and AI algorithms to assess hemodynamic parameters for heart failure and pulmonary hypertension patients without invasive catheterization. Sensydia's CPS platform is currently undergoing a multi-center pivotal study to support its FDA submission and commercialization.